NCT03842943View on ClinicalTrials.gov

Neoadjuvant Combination Immunotherapy for Stage III Melanoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 3, 2019

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2028

Conditions
Cutaneous Melanoma
Interventions
DRUG

Pembrolizumab

Preoperative infusions

DRUG

Talimogene Laherparepvec

Preoperative intralesional injection

Trial Locations (1)

40202

RECRUITING

University of Louisville, Louisville

All Listed Sponsors
lead

University of Louisville

OTHER